newsfilter
← Latest News
GlobeNewswire·

VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023